^
Association details:
| Biomarker: | EGFR A763_Y764insFQEA |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FP12.05 - The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC
Published date:
08/18/2021
Excerpt:
Two patients showed EGFR A763_Y764insFQEA, which has been considered as sensitive to classical EGFR tyrosine kinase inhibitors (EGFR-TKIs). Two patients (EGFR A763_Y764insFQEA and EGFR T751_I759>S) had received erlotinib during their treatment course and both of them showed stable disease with a progression-free survival of 5.9 and 10.1 months, respectively.
